Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice expressing nuclear sterol regulatory element binding protein-1c in adipose tissue

International Journal of Molecular Medicine

Volumn 24, Issue 1, 2009, Pages 17-22

  Ueno, Takato ^a   Torimura, Takuji ^b   Nakamura, Toru ^b   Sivakumar, Ramadoss ^a   Nakayama, Hitomi ^c   Otabe, Syuichi ^c   Yuan, Xiaohong ^c   Yamada, Kentaro ^c   Hashimoto, Osamu ^b   Inoue, Kinya ^b   Koga, Hironori ^b   Sata, Michio ^b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Green tea polyphenol; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Nuclear sterol regulatory element binding protein 1c

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALANINE AMINOTRANSFERASE; ASCORBIC ACID; CHOLESTEROL; EPIGALLOCATECHIN GALLATE; GLUCOSE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; C57BL 6 MOUSE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER WEIGHT; LOW DRUG DOSE; MALE; MALLORY BODY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADIPOSE TISSUE; ANIMALS; CATECHIN; DEOXYGUANOSINE; FATTY LIVER; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER; MICE; MICE, TRANSGENIC; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 67649522012     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000200     Document Type: Article

References (31)

1. Yoshiike N and Lwin H: Epidemiological aspects of obesity and NASH/NAFLD in Japan. Hepatol Res 33: 77-82, 2005.
2. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K and Shiratori K: The characteristics and natural history of Japanese patients with nonalcoholic fatty liver diseases. Hepatol Res 33: 72-76, 2005.
3. Ono M and Saibara T: Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature. J Gastroenterol 41: 725-732, 2006.
4. Harrison SA, Kadakia S, Lang KA and Schenker S: Nonalcoholic steatohepatits: what we know in the new millennium. Am J Gastroenterol 97: 2714-2724, 2002.
5. Ludwig J, Viggiano TR, McGill DB and Ott BJ: Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980.
6. Powel EE, Cooksley WG, Hanson R, Searle J, Halliday JW and Powell JW: The natural history of steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11: 74-80, 1990.
7. Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, Tokushige K and Shiratori K: Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma and burnt-out NASH. J Gastroenterol 39: 1215-1218, 2004.
8. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M and Rizzetto M: Expanding the natural history of NASH: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134-140, 2002.
9. Nakayama H, Otabe S, Ueno T, Hirota N, Yuan X, Fukutani T, Hashinaga T, Wada N and Yamada K: Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 56: 470-475, 2007.
10. Bose M, Lambert JD, Ju J, Reuhl KR and Shapses SA: The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 138: 1677-1683, 2008.
11. Lee SM, Kim CW, Kim JK, Shin HJ and Baik JH: GCG-rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats. Lipids 43: 419-429, 2008.
12. Murase T, Nagasawa A, Suzuki J, Hase T and Tokimitsu I: Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes 26: 1459-1464, 2002.
13. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL and Brown MS: Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12: 3182-3194, 1998.
14. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419, 1999.
15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ and Sanyal AJ: Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.
16. Korenblat KM, Fabbrini E, Mohammed BS and Klein A: Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134: 1369-1375, 2008.
17. Sanyal AJ: Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pra Gastroenterol Hepatol 2: 46-53, 2005.
18. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
19. Sakata R, Ueno T, Nakamura T, Sakamoto M, Torimura T and Sata M: Green tea polyphenol epigallocatechin-3-gallate inhibits platelet-derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol 40: 52-59, 2004.
20. Chen A, Zhang L, Xu J and Tang J: The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression. Biochem J 368: 695-704, 2002.
21. Zhen M, Wang Q, Huang X, Cao L, Chen X, Sun K, Liu YJ, Li W and Zhang LJ: Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J Nutr Biochem 18: 795-805, 2007.
22. Yumei F, Zhou Y, Zheng S and Chen A: The antifibrogenic effect of (-)-epigallocatechin gallate results from the induction of de novo synthesis of glutathione in passaged rat hepatic stellate cells. Lab Invest 86: 697-709, 2006.
23. Fu Y, Zheng S, Lu SC and Chen A: Epigallocatechin-3-gallate inhibits growth of activated hepatic stellate cells by enhancing the capacity of glutathione synthesis. Mol Pharmacol 73: 1465-1473, 2008.
24. Csala M, Margitti E, Senesi S, Gamberucci A, Banhegyi G, Mandl J, et al: Inhibition of hepatic glucose 6-phosphatase system by the green tea flavanol epigallocatechin gallate. FEBS Lett 581: 1693-1698, 2007.
25. Collins QF, Liu H, Pi J, Liu Z, Quon MJ and Cao W: Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase. J Biol Chem 282: 30143-30149, 2007.
26. Igarashi K, Honma K, Yoshinari O, Nanjo F and Hara Y: Effects of dietary catechins on glucose tolerance, blood pressure and oxidative status in Goto-Kakizaki rats. J Nutr Sci Vitaminol 53: 496-500, 2007.
27. Nagao T, Komine Y, Soga S, Meguro S, Hase T, Tanaka Y and Tokimitsu I: Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J Clin Nutr 81: 122-129, 2005.
28. Angulo P: NAFLD, obesity, and bariatric surgery. Gastroenterology 130: 1848-1852, 2006.
29. Bataller R, Sancho-Bru P, Gines P and Brenner DA: Liver fibrogenesis: a new role for the rennin-angiotensin system. Antioxid Redox Signal 7: 1346-1355, 2005.
30. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S and Ananina FA: The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 166: 1655-1669, 2005.
31. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Torbenson M, Smedh U, Moran TH, Li Z, Huang J, Thomas SA and Diehl AM: Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 53: 438-445, 2004.